Suppression of tumor suppressors in prostate cancer: the emergence of a novel oncogenic pathway.

Abstract

Elucidating oncogenic pathways in prostate cancer is an arduous task. In this issue of Cancer Cell, Yu and colleagues show that repression of Adrenergic Receptor Beta-2 gene expression by Enhancer of Zeste 2 results in acquisition of transforming activities. It is interesting that these activities point to a role for GTPases as important regulators of transformation in prostate cancer cells. They further implicate epithelial-mesenchymal transition as a biologic end point in this process. Overall, on the basis of their findings, the authors nominate a novel oncogenic pathway for prostate cancer that deserves critical thought and attention.

• Authors: Timothy C Thompson
• Journal: Cancer cell (Cancer Cell) Vol. 12 Issue 5 Pg. 405-7 (Nov 2007) ISSN: 1535-6108 [Print] United States
• PMID: 17996641 (Publication Type: Journal Article, Comment)

Chemical References

• Receptors, Adrenergic, beta-2
• Shelterin Complex
• TERF2IP protein, human
• Telomere-Binding Proteins
• Cyclic AMP
• GTP Phosphohydrolases

Topics

• Animals
• Cell Line, Tumor
• Cyclic AMP (metabolism)
• GTP Phosphohydrolases (metabolism)
• Gene Expression Regulation, Neoplastic
• Humans
• Male
• Models, Biological
• Oncogenes (genetics)
• Phenotype
• Prostatic Neoplasms (pathology)
• Receptors, Adrenergic, beta-2 (metabolism)
• Shelterin Complex
• Telomere-Binding Proteins (metabolism)